Webinar Series 7 Episode 2

With advancement in drug development technologies, the discrepancies we continue to observe between pre-clinical drug research and final clinical trial outcomes are being scrutinized more closely than even before.

As therapeutic modes are diversifying to include new drug formats and biological agents, the clinical translation capabilities of traditional approaches have becomes more strained. The expression of human drug targets, enzymes, transporters, receptors, and interacting proteins are crucial to the successful assessment of drug candidates.

Without these capabilities embedded into the preclinical assessment process, drug candidates are likely to be incorrectly categorized, and either put forward at risk or wrongly removed from the development pipeline following in vitro testing.

In this MPS Webinar, we discuss how the PhysioMimix® OOC System can be used to develop human and preclinical animal microphysiological systems (MPS), also known as Organ-on-a-chip (OOC), to decrease the informational divide between in vitro assessment, in vivo testing, and the clinic; especially to uncover potential Drug induced liver injury / hepatotoxicity risks.

MPS/OOC offer the ultimate clinical translation tool that produces physiologically relevant data in vitro, to better guide in vivo experimental design; reduce your reliance on animal testing, and allow greater confidence in progressing drug candidates to successful clinical trials.

Key learning Objectives

• Determine how you can leverage liver MPS to predicting DILI risks
• Understand the current challenges of preclinical (in vitro & in vivo assessment) to clinical translation in drug development
• Identify where MPS/OOC best fit within your drug discovery and development pipelines
• Find out how MPS/OOC technology can be implemented into your workflows
• Learn about the PhysioMimix human and preclinical animal liver-on-a-chip / MPS models and how they recapitulate the functionality of the liver in vitro